Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea

Purpose: Inflammation and oxidative stress play important roles in the pathogenesis of obstructive sleep apnoea syndrome (OSAS). Omentin is expressed in visceral adipose tissue and is associated with the inflammatory response. The aim of this study was to assess the relationship between OSAS and omentin based on a comparison of its serum levels at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. Methods: Ninety-six newly diagnosed OSAS patients and 31 non-apnoeic controls were enrolled in this study. Blood samples were obtained in the morning after polysomnography. Within the OSAS group, 30 patients were started on CPAP therapy and then reassessed clinically, including a blood test for serum omentin and other biochemical analysis, at 3 months. Results: Serum omentin levels were significantly lower in the OSAS group than in the control group (27.7 ± 7.6 and 42.5 ± 5.2 ng/mL, P < 0.001). In the subgroup analysis, omentin concentrations were significantly lower in patients with severe OSAS than in those with mild/moderate OSAS (P < 0.001). Circulating omentin levels were significantly correlated with the apnoea–hypopnoea index (AHI), mean SaO2, oxygen desaturation index, and serum C-reactive protein levels. Treatment with CPAP resulted in a significant increase in circulating omentin levels after 3 months, from 22.7 ± 1.4 to 41.2 ± 3.3 ng/mL (P < 0.001). Conclusions: OSAS is associated with low serum omentin levels, and these levels can be reversed by effective CPAP treatment. © 2016, Springer-Verlag Berlin Heidelberg.

Yazar Uygur F.
Tanrıverdi H.
Can M.
Erboy F.
Altınsoy B.
Atalay F.
Ornek T.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4408
Tek Biçim Adres 10.1007/s11325-016-1315-2
Konu Başlıkları Cardiovascular diseases
Continuous positive airway pressure
Inflammation
Obstructive sleep apnoea syndrome
Omentin
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Sleep and Breathing
Dergi Cilt Bilgisi 20
Dergi Sayısı 3
Sayfalar 939 - 945
Yayın Yılı 2016
Eser Adı
[dc.title]
Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea
Yazar
[dc.contributor.author]
Uygur F.
Yazar
[dc.contributor.author]
Tanrıverdi H.
Yazar
[dc.contributor.author]
Can M.
Yazar
[dc.contributor.author]
Erboy F.
Yazar
[dc.contributor.author]
Altınsoy B.
Yazar
[dc.contributor.author]
Atalay F.
Yazar
[dc.contributor.author]
Ornek T.
Yayın Yılı
[dc.date.issued]
2016
Yayıncı
[dc.publisher]
Springer Verlag
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Purpose: Inflammation and oxidative stress play important roles in the pathogenesis of obstructive sleep apnoea syndrome (OSAS). Omentin is expressed in visceral adipose tissue and is associated with the inflammatory response. The aim of this study was to assess the relationship between OSAS and omentin based on a comparison of its serum levels at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. Methods: Ninety-six newly diagnosed OSAS patients and 31 non-apnoeic controls were enrolled in this study. Blood samples were obtained in the morning after polysomnography. Within the OSAS group, 30 patients were started on CPAP therapy and then reassessed clinically, including a blood test for serum omentin and other biochemical analysis, at 3 months. Results: Serum omentin levels were significantly lower in the OSAS group than in the control group (27.7 ± 7.6 and 42.5 ± 5.2 ng/mL, P < 0.001). In the subgroup analysis, omentin concentrations were significantly lower in patients with severe OSAS than in those with mild/moderate OSAS (P < 0.001). Circulating omentin levels were significantly correlated with the apnoea–hypopnoea index (AHI), mean SaO2, oxygen desaturation index, and serum C-reactive protein levels. Treatment with CPAP resulted in a significant increase in circulating omentin levels after 3 months, from 22.7 ± 1.4 to 41.2 ± 3.3 ng/mL (P < 0.001). Conclusions: OSAS is associated with low serum omentin levels, and these levels can be reversed by effective CPAP treatment. © 2016, Springer-Verlag Berlin Heidelberg.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Cardiovascular diseases
Konu Başlıkları
[dc.subject]
Continuous positive airway pressure
Konu Başlıkları
[dc.subject]
Inflammation
Konu Başlıkları
[dc.subject]
Obstructive sleep apnoea syndrome
Konu Başlıkları
[dc.subject]
Omentin
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1520-9512
İlk Sayfa Sayısı
[dc.identifier.startpage]
939
Son Sayfa Sayısı
[dc.identifier.endpage]
945
Dergi Adı
[dc.relation.journal]
Sleep and Breathing
Dergi Sayısı
[dc.identifier.issue]
3
Dergi Cilt Bilgisi
[dc.identifier.volume]
20
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s11325-016-1315-2
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4408
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
35
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
09 Şubat 2024 12:39
Google Kontrol
Tıklayınız
omentin levels significantly 3 months patients therapy analysis associated apnoea–hypopnoea control correlated Circulating 2 ng/mL subgroup concentrations mild/moderate severe Purpose 3 ng/mL Heidelberg Berlin Springer-Verlag treatment effective reversed Conclusions circulating increase significant resulted Treatment C-reactive desaturation oxygen protein
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms